Pancreatic cancer is an oncogene-driven tumor disease.42 The classic molecular profile is formed by a pathogenic KRAS mutation (90% of patients, predominantly codon 12) along with inactivation of one or more classic tumor suppressors (CDKN1A 20%, CDKN2A 90%, SMAD4 60-90%, TP53 50-70%). Here, KRAS is linked to neoplasm.